deltatrials
Completed PHASE3 NCT00250471

PROTECT-TIMI 30 Trial

A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Unstable Angina
Interventions Percutaneous Coronary Intervention (PCI)
Updated 4 times since 2017 Last updated: Nov 7, 2005 Started: May 31, 2003 Completion: Sep 30, 2004

A PHASE3 clinical study on Unstable Angina, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 4 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE3

    First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Millennium Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.